Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.
Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.
<<<
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More